deltatrials
Completed PHASE3 NCT00167154

Risperidone and Suicidality in Major Depressive Disorder

Efficacy of Risperidone in the Management of Suicidality in Major Depressive Disorder

Sponsor: Janssen Pharmaceuticals

Conditions Depression
Interventions Risperidone and placebo comparator
Updated 7 times since 2017 Last updated: Jun 8, 2021 Started: Jun 30, 2004 Primary completion: Apr 30, 2007 Completion: Aug 31, 2008

This PHASE3 trial investigates Depression and is currently completed. Janssen Pharmaceuticals leads this study, which shows 7 recorded versions since 2004 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Sep 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Sep 2021 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jun 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen Pharmaceuticals
  • University of Alabama at Birmingham
Data source: University of Alabama at Birmingham

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Birmingham, United States